Vaccine also offers 65% protection against Delta variant, according to firmHyderabad-based Bharat Biotech India Ltd (BBIL) on July 3 publicised the long-awaited results of the Phase-3 trial of Covaxin that involved nearly 25,800 volunteers spanning 25 hospitals across the country. This is higher than the overall 70.4% efficacy reported from the Phase-3 trial results of the AstraZeneca (Covishield) vaccine published in Lancet in January. Moreover, it was 65% protective against the Delta variant. The reported 93.5% is very good, and protection in those over 60 as well as against the Delta variant too are encouraging,” Dr. Kalantri added. Covaxin has now received emergency use authorisation in 16 countries, including Brazil, India, Philippines, Iran, Mexico, and is in process in 50 countries worldwide.

Source: The Hindu July 03, 2021 04:44 UTC